New heart drug trial for rare, stiff heart condition
NCT ID NCT07240844
Summary
This study is testing whether a drug called Enavogliflozin can help people with amyloid cardiomyopathy, a rare disease where abnormal proteins stiffen the heart. About 68 participants with heart failure symptoms will take the drug and a placebo in separate 12-week periods to see which one better improves their quality of life and ability to exercise. The main goal is to see if the drug is safe and effective at managing this serious condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYLOID CARDIOMYOPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Samsung Medical Center
Seoul, 06351, South Korea
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Seoul St. Mary's Hospital, The Catholic University of Korea
Seoul, 06591, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.